• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Thèse de Doctorat
DOI
https://doi.org/10.11606/T.5.2021.tde-06122021-143038
Document
Auteur
Nom complet
João Paulo Maciel da Silva
Adresse Mail
Unité de l'USP
Domain de Connaissance
Date de Soutenance
Editeur
São Paulo, 2021
Directeur
Jury
Coelho, Fabricio Ferreira (Président)
Herman, Paulo
Linhares, Marcelo Moura
Szor, Daniel José
Titre en portugais
Impacto dos marcadores inflamatórios no prognóstico de pacientes com carcinoma hepatocelular submetidos à ressecção hepática com intenção curativa
Mots-clés en portugais
Análise de sobrevida
Carcinoma hepatocelular
Hepatectomia
Inflamação
Linfócitos
Neutrófilos
Plaquetas
Prognóstico
Resumé en portugais
Introdução: O algoritmo terapêutico do carcinoma hepatocelular (CHC) é complexo e tem na ressecção cirúrgica um dos seus principais alicerces. Contudo, a recidiva pós-operatória ainda é alta, variando de 50 a 80% em 5 anos. Por esta razão, a busca por fatores prognósticos que possam refinar o entendimento da biologia e comportamento tumorais tem aumentado. Estudos recentes têm demonstrado a relação entre a resposta inflamatória e o prognóstico oncológico de diversas neoplasias sólidas gastrointestinais. Entretanto, o impacto prognóstico dos marcadores inflamatórios em pacientes submetidos à hepatectomia por CHC ainda é pouco conhecido. Os estudos existentes têm mostrado resultados promissores, no entanto, são, em sua maioria, oriundos de centros orientais, com características tumorais e epidemiológicas distintas das encontradas em centros ocidentais. Objetivo: O objetivo primário é avaliar o impacto prognóstico dos principais marcadores inflamatórios pré-operatórios relação neutrófilo-linfócito (RNL), relação plaqueta-linfócito (RPL) e relação monócito-linfócito (RML) no desfecho oncológico de pacientes submetidos à hepatectomia curativa por CHC. O objetivo secundário é estudar o impacto destes marcadores em subgrupos de pacientes com CHC quanto ao seu tamanho: < 5 cm, entre 5 e 10 cm e > 10 cm. Método: Foram estudados, tendo como base um banco de dados prospectivo, pacientes operados de janeiro de 2007 a dezembro de 2018. Os critérios de exclusão foram: doença extra-hepática, ressecção R1/R2 e tratamentos locorregionais prévios. Os melhores cut-offs para a RNL, RPL e RML foram calculados a partir da construção de curvas ROC (Receiver Operator Curve) e do índice de Youden, dividindo-se os pacientes em 2 grupos, acima e abaixo do cut-off calculado. As sobrevidas, global (SG) e livre de doença (SLD), foram estimadas por meio do método de Kaplan-Meier e comparadas pelo teste de log-rank. O método de Cox foi utilizado para identificar fatores independentes associados à SG e SLD. O nível de significância foi 5%. Resultado: Foram incluídos 161 pacientes. Com base na curva ROC, os melhores pontos de corte relacionados à mortalidade foram: RNL (1,715), RPL (115,05) e RML (1,750). Para recidiva, os pontos de corte foram: RNL (2,475), RPL (100,25) e RML (2,680). A RNL elevada ( > 1,715) associou-se à pior SG (p=0,018). A RNL ( > 2,475; p=0,047) e RPL ( > 100,25; p=0,028) elevadas associaram-se à pior SLD. Em pacientes com CHC < 5 cm, a RML ( > 1,715) foi associada à menor SG (p=0,047). Na análise multivariada, a hipertensão portal (HR=7,04; IC95% 2,40-20,66; p < 0,001), AST > 50 U/dL (HR=3,06; IC95% 1,10-8,47; p=0,032) e tempo em UTI > 3 dias (HR=5,04; IC95% 1,75-14,49; p=0,003) foram fatores associados à pior SG. Quanto à SLD, AST > 50 U/dL (HR=3,32; IC95% 1,60-6,91; p=0,001), invasão vascular (HR=2,36; IC95% 1,13-4,93 p=0,022) e RPL elevada (HR=3,03 IC95% 1,50-6,12; p=0,002) foram independentemente associados à maior recidiva. Conclusão: RNL elevada foi associada à menor SG e SLD. A RPL elevada foi preditora independente de pior SLD. A RML elevada foi preditora de menor SG em pacientes com CHC < 5 cm
Titre en anglais
Prognostic impact of inflammatory markers in patients with hepatocellular carcinoma who underwent hepatic resection with curative intent
Mots-clés en anglais
Hepatectomy
Hepatocellular carcinoma
Inflammation
Lymphocytes
Neutrophils
Platelets
Prognosis
Survival analysis
Resumé en anglais
Background: The therapeutic decision algorithm for hepatocellular carcinoma (HCC) is complex and has surgical resection as the mainstay of treatment. However, the post-operative recurrence of hepatocellular carcinoma is still high, reaching 5080% in five years. For this reason, the search for prognostic markers that may help shed more light on tumor biology has been growing. For instance, the relationship between the inflammatory response and the oncologic prognosis of solid gastrointestinal tumors has recently been accessed. The available studies, reported from a majority derived of Eastern centers, have shown promising outcomes involving distinct tumor and epidemiologic features, in comparison to their Western counterparts. Despite this, the impact of inflammatory markers in oncologic outcomes of patients who underwent hepatectomy for HCC is still poorly known in general. Aim: The primary endpoint was to evaluate the prognostic impact of the main pre-operative inflammatory markersneutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)in the long-term outcomes of patients who underwent curative hepatectomy for HCC. The secondary endpoint was to evaluate the prognostic impact of these markers in subgroups of patients according to tumor size: < 5 cm, 510 cm, and > 10 cm. Method: A prospective database was utilized to study patients who underwent HCC resection from January 2007 to June 2018. The exclusion criteria were as follows: extra-hepatic disease; R1/R2 resection, and preoperative locoregional treatments. The best cut-off values for NLR, PLR and MLR were calculated through Receiver Operator Characteristic (ROC) curve analysis using the Youdens index. Thereafter, patients were divided into two groups: those below and above the calculated cut-offs. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method and compared by the log-rank test. The Cox method was used to identify independent predictors associated with OS and DFS. The significance level used was set to 5%. Results: A total of 161 patients were enrolled. Based on the ROC curve analysis, the best cut-offs regarding mortality were the following: NLR (1.715), PLR (115.05), and MLR (1.750). For recurrence, the best cut-offs were NLR (2.745), PLR (100.25), and MLR (2.680). A high NLR (1.715) was associated with worse OS (p=0.018). High NLR (>2,475; p=0.047) and PLR ( > 100.25; p=0.028) were associated with worse DFS. In HCC < 5 cm, the MLR ( < 1.715) was associated with worse OS (P=0.047). In multivariate analysis, portal hypertension (hazard ratio [HR]=7.04; 95% confidence interval [CI] 2.40-20.67; p < 0.001), aspartate aminotransferase (AST) > 50 U/dL (HR=3.06; 95% CI 1.10-8.47; p=0.032), and ICU stay > 3 days (HR=5.04; 95% CI 1.75-14.49; p=0.003) were factors associated with worse OS. For DFS, AST > 50 U/dL (HR=3.32; 95% CI 1.60-6.91; p=0,001), vascular invasion (HR=2.36; 95% CI 1.13-4.93 p=0.022), and elevated PLR (HR=3.03; 95% CI 1.50-6.12; p=0.002) were independent predictors for higher recurrence. Conclusions: An elevated NLR was related to worse OS and DFS. An elevated PLR was an independent predictor of worse DFS. An elevated MLR was a predictor of worse OS in patients with HCC < 5 cm
 
AVERTISSEMENT - Regarde ce document est soumise à votre acceptation des conditions d'utilisation suivantes:
Ce document est uniquement à des fins privées pour la recherche et l'enseignement. Reproduction à des fins commerciales est interdite. Cette droits couvrent l'ensemble des données sur ce document ainsi que son contenu. Toute utilisation ou de copie de ce document, en totalité ou en partie, doit inclure le nom de l'auteur.
Date de Publication
2021-12-14
 
AVERTISSEMENT: Apprenez ce que sont des œvres dérivées cliquant ici.
Tous droits de la thèse/dissertation appartiennent aux auteurs
CeTI-SC/STI
Bibliothèque Numérique de Thèses et Mémoires de l'USP. Copyright © 2001-2024. Tous droits réservés.